BRAF vs RAS oncogenes: are mutations of the same pathway equal? Differential signalling and therapeutic implications.

However, a more recent study supports that even though KRAS tumour mutation status has no major prognostic value for relapse-free and OS in patients with stage II and III CRC treated with adjuvant chemotherapy, it may actually have slightly significant prognostic value when observed in the multivariate analysis of the MSI-L/ and MSS subpopulation [ 80 ].

also in 1,762 other papers